Navigation Links
VGXI Recognized as Best CMO Finalist for the 2020 Vaccine Industry Excellence Awards
Date:3/4/2020

VGXI, Inc., a uniquely specialized CDMO providing high quality plasmid DNA-based products and services, announced it has been nominated as a finalist in the category of Best Contract Manufacturing Organization for the annual Vaccine Industry Excellence (ViE) Awards. This nomination comes as VGXI expedites manufacturing of a DNA vaccine against the novel coronavirus, COVID-19, under a CEPI funded collaboration.

The ViE Awards highlight the accomplishments and positive contributions of companies and individuals across the vaccine industry. Shortlisted finalists for each of the 12 award categories are determined by industry nominations and voting over a 3 month period. The ViE Scientific Advisory Board oversees the final judging round.

“VGXI’s nomination for Best CMO is a testament to our company’s reputation among industry leaders, our clients, and our partners,” stated VGXI COO Dorothy Peterson. “With nearly 20 years of experience, we have established a track record of success in delivering exceptional results for our client’s challenging projects.”

As part of the annual World Vaccine Congress in Washington DC, winners in each category will be announced at the ViE Awards Ceremony & Gala Dinner on April 7th, 2020.

VGXI will also be exhibiting at Booth #310 during the WVC conference. Requests for partnering meetings during the event are welcome and can be submitted at the VGXI website: http://vgxii.com/contact-us/

ABOUT VGXI, INC.
VGXI, Inc. is a leading provider of manufacturing and development services for DNA vaccines and gene therapies. The company has a reputation of success in manufacturing DNA products under cGMP conditions for clinical trials in the US, EU, Asia, Canada, and Australia, and its cGMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and experienced development team. VGXI, Inc. is a wholly-owned subsidiary CDMO of GeneOne Life Science, Inc. To learn more, visit http://www.vgxii.com.

ABOUT GENEONE LIFE SCIENCE
GeneOne Life Science Inc. (“GeneOne” KOSPI: 011000) is an international DNA vaccine and product developer, and leading contract manufacturer of DNA plasmid-based agents for pre-clinical and clinical trials for global companies and institutions. It researches and develops DNA vaccines and products to prevent and treat incurable diseases in South Korea and internationally. The company is headquartered in Seoul, South Korea. VGXI, Inc., GeneOne's wholly-owned manufacturing subsidiary located in Texas, is the largest pure-play cGMP DNA plasmid manufacturing facility in the world. For more information, visit http://www.genels.com/en.

CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS
Materials in this press release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They include words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of GeneOne stock. It is also important to read the disclosure notice contained in many of the individual GeneOne documents available on the website, as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

Read the full story at https://www.prweb.com/releases/vgxi_recognized_as_best_cmo_finalist_for_the_2020_vaccine_industry_excellence_awards/prweb16958172.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology news :

1. NREL staff recognized for breakthrough technologies
2. PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace
3. Temples Dr. Steven Houser recognized by the American Heart Association
4. Entomologist recognized for exceptional service to Californias vegetable industry
5. UMass Medical School faculty recognized as 1 of nations top young scientists
6. OU professor recognized by AAAS for pioneering efforts to advance ecological forecasting
7. Pioneer Award recipients Marina Cavazzana and Adrian Thrasher recognized for advancing gene therapy to the clinic for immunodeficiency disorders
8. NREL staff recognized for top innovations
9. NSF-managed US Antarctic Program recognized for its search-and-rescue efforts
10. Facilitating transparency in spinal cord injury studies using recognized information standards
11. Fierce Innovation Awards: Healthcare Edition Program Announces Finalists, BIOCLAIM, Inc. Recognized
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2020)... ... July 08, 2020 , ... ... Gene Therapy Regulation, An FDAnews Webinar, Wednesday, July 22, 2020 • 1:30 p.m.-3:00 ... but what is the most effective way to complete one? Will the study ...
(Date:7/1/2020)... SOMERSET, N.J. (PRWEB) , ... July 01, 2020 ... ... today announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility ... with the company’s existing Japanese clinical supply facility located in Kakegawa, the new ...
(Date:6/23/2020)... (PRWEB) , ... June 23, ... ... provider of gene-to-protein and monoclonal antibody development services, today announced that the ... products and services to the pharmaceutical, diagnostics, and research industries. The decision ...
Breaking Biology News(10 mins):
(Date:7/22/2020)... TORONTO (PRWEB) , ... July 22, 2020 , ... Join ... and John Lorenc, Sr. Manager Regulatory Solutions, in a one hour live webinar ... is the regulating body in China for drugs and medical devices. Specifically, for medical ...
(Date:7/10/2020)... ... July 08, 2020 , ... ... products, announces a significant expansion of laboratory operations through its COVID-19 testing ... implementing testing programs. , Bode-CARES provides a turnkey solution that ...
(Date:7/7/2020)... ... July 06, 2020 , ... Bio-IT World has announced the ... Squibb, the University of Chicago, Massachusetts General Hospital, Mission: Cure, and the Pistoia ... program, highlighting outstanding examples of how technology innovations and strategic initiatives can be ...
(Date:6/28/2020)... ... 25, 2020 , ... With the COVID-19 pandemic impacting millions ... In an effort to better understand the cellular responses to COVID-19, the digital ... portraying therapeutic compound effects from over 1,600 approved and referenced molecules on SARS-CoV-2-infected ...
Breaking Biology Technology: